Adherence Outcomes and Risk Factors Predicting Nonadherence to Active Surveillance in Patients With Stage 1 Testicular Germ Cell Tumors

被引:1
作者
Liang, Roger [1 ,2 ,3 ]
Adams, Diana [2 ]
Roncolato, Felicia [2 ]
Asghari, Ray [3 ]
Descallar, Joseph [4 ,5 ]
Pal, Abhijit [1 ,3 ]
Chua, Wei [1 ]
Balakrishnar, Bavanthi [1 ]
机构
[1] Liverpool Hosp, Canc Therapy Ctr, Liverpool, NSW, Australia
[2] Campbelltown Hosp, Macarthur Canc Therapy Ctr, Campbelltown, NSW, Australia
[3] Bankstown Lidcombe Hosp, Bankstown Canc Ctr, Bankstown, NSW, Australia
[4] Ingham Inst Appl Med Res, Liverpool, NSW, Australia
[5] UNSW Sydney, Sch Clin Med, South West Sydney Clin Campuses, Sydney, NSW, Australia
关键词
Compliance; Follow-up; Testicular cancer; Surveillance appointment; Recurrence detection; FOLLOW-UP; CANCER; RELAPSE;
D O I
10.1016/j.clgc.2024.102116
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Adherence with active surveillance for stage 1 testicular cancer is often suboptimal. This retrospective study assessed adherence to active surveillance and analyzed factors impacting adherence. This cohort had a high rate of loss to follow-up of 38%. Significant risk factors for nonadherence included being from nonculturally and linguistically diverse background, employment, smoking, single relationship status, and earlier date of diagnosis. Purpose: Adherence to active surveillance in patients with stage 1 testicular cancers may be influenced by factors affecting capacity and motivation to attend appointments. The aims of this study were to assess adherence to active surveillance and analyze factors which may impact adherence. Patients and Methods: A retrospective cohort study was conducted in patients diagnosed with stage 1 testicular cancer between 2005 and 2020, and managed with active surveillance at 3 institutions in South Western Sydney, Australia. Adherence with active surveillance was followed to 2023 and patients were subsequently classified into 3 groups: "Optimal," "Adequate" or "Loss to follow-up" (LTFU). Factors for adherence were analyzed using multivariable logistic regression. Disease recurrence was analyzed using multivariable Cox regression. Results: In 125 patients, adherence with active surveillance was assessed as "Optimal" in 64 (51%), "Adequate" in 14 (11%), and LTFU in 47 (38%). Multivariable analysis demonstrated that patients had higher odds of being in the "Optimal" or "Adequate" categories if they were from a culturally and linguistically diverse background (OR 4.86, P = .026), nonsmokers (OR 7.63, P = .0002), not employed (OR 4.93, P = .0085), had a partner (OR 2.74, P = .0326), or were diagnosed after June 2016 (OR 5.22, P = .0016). Recurrence occurred in 21 patients (17%). The risk of recurrence increased with the presence of multiple pathological risk factors (HR 5.77, P = .0032), if patients were unemployed (HR 2.57, P = .032), or if they had "Optimal" or "Adequate" adherence (HR 12.74, P = .0136). Conclusion: Adherence with active surveillance was poorer in this cohort of stage 1 testicular cancer patients. Patients from culturally and linguistically diverse backgrounds and those who were nonsmokers, unemployed, with a partner, and later date of diagnosis, were more likely to be adherent with active surveillance.
引用
收藏
页数:7
相关论文
共 25 条
[1]   Patterns of care and outcomes of men with germ cell tumors in a high-volume Australian center [J].
Arasaratnam, Malmaruha ;
Balakrishnar, Bavanthi ;
Crumbaker, Megan ;
Turner, Sandra ;
Hayden, Amy J. ;
Brooks, Andrew ;
Patel, Manish, I ;
Lau, Howard ;
Woo, Henry ;
Bariol, Simon ;
Gurney, Howard .
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2022, 18 (02) :E23-E31
[2]  
Australian and New Zealand Urogenital and Prostate (ANZUP) Cancer Trial Group, 2023, ANZUP Stage 1 Testicular Cancer Surveillance Recommendations
[3]  
Australian Institute of Health and Welfare, 2023, Cancer data in Australia
[4]  
BC Cancer Agency, 2013, Cancer Management Manual: Testis
[5]   Compliance with follow-up for patients with stage 1 testicular germ cell tumour [J].
Cheung, King Tung ;
Dat, Anthony ;
Wong, Peter ;
Dowling, Caroline ;
Davis, Ian D. ;
Sengupta, Shomik .
ANZ JOURNAL OF SURGERY, 2021, 91 (1-2) :184-186
[6]   Late results of surveillance of clinical stage I nonseminoma germ cell testicular tumours: 17 years' experience in a national study in New Zealand [J].
Colls, BM ;
Harvey, VJ ;
Skelton, L ;
Frampton, CMA ;
Thompson, PI ;
Bennett, M ;
Perez, DJ ;
Dady, PJ ;
Forgeson, GV ;
Kennedy, ICS .
BJU INTERNATIONAL, 1999, 83 (01) :76-82
[7]   Patterns of Relapse in Australian Patients With Clinical Stage 1 Testicular Cancer: Utility of the Australian and New Zealand Urogenital and Prostate Cancer Trials Group Surveillance Recommendations [J].
Conduit, Ciara ;
Lewin, Jeremy ;
Weickhardt, Andrew ;
Lynam, James ;
Wong, Shirley ;
Grimison, Peter ;
Sengupta, Shomik ;
Pranavan, Ganes ;
Parnis, Francis ;
Bastick, Patricia ;
Campbell, David ;
Hansen, Aaron R. ;
Leonard, Matt ;
Mcjannett, Margaret ;
Stockler, Martin R. ;
Gibbs, Peter ;
Toner, Guy ;
Davis, Ian D. ;
Tran, Ben ;
Kuchel, Anna .
JCO ONCOLOGY PRACTICE, 2023, 19 (11) :973-+
[8]   Improving adherence and health outcomes in testicular cancer survivors using a mobile health-based intervention: A mixed-methods pilot study [J].
Deleemans, Julie M. ;
Samnani, Sunil ;
Lloyd, Chris ;
Alimohamed, Nimira .
DIGITAL HEALTH, 2023, 9
[9]   Risk Factors for Loss to Follow-up During Active Surveillance of Patients with Stage I Seminoma [J].
Endo, Tsuyoshi ;
Kawai, Koji ;
Kamba, Tomomi ;
Inai, Hiromu ;
Uchida, Kazunori ;
Miyazaki, Jun ;
Kamoto, Toshiyuki ;
Ogawa, Osamu ;
Nishiyama, Hiroyuki .
JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2014, 44 (04) :355-359
[10]  
Ernst D Scott, 2005, Can J Urol, V12, P2575